Study of a virus treatment delivered into liver arteries
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests an oncolytic (tumor-attacking) virus given directly into liver arteries using a catheter. It’s for people with advanced liver cancer who have already tried standard treatments or can’t have them, aiming to assess safety and early anti-cancer activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to the study and sign informed consent before any study procedures
- You are 18–75 years old, and you have liver cancer (primary or spread) confirmed by lab tests
- Your cancer has not responded to standard treatment, or you can’t or don’t want standard treatment
- Your overall performance status is 0 or 1, and your liver function is Child-Pugh A or B
- Your blood counts and organ tests are within allowed ranges on labs done within 7 days before treatment
- If you have hepatitis B or C, you must be on the right antiviral treatment and meet liver-function requirements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This Phase 1 trial tests VG161, a study medicine, given by injection into liver or nearby tumors for people with advanced primary liver cancer that has not responded to standard treatment (or there is no standard option). The goal is to find a safe dose and see how the tumors respond.
This trial is testing a new combination: a virus injected directly into the tumor, plus two drugs (tislelizumab and lenvatinib) that boost the immune system and block tumor blood supply. It is for people with advanced liver cancer who have not had similar treatments before.
This Phase 1 study tests OH2 given as an injection directly into certain tumors (intratumoral injection) in people with advanced melanoma or several other solid cancers that are hard to remove. It aims to see whether the treatment is safe and if it can help control cancer by reaching the tumor more directly.
This early-phase trial tests a cancer-killing virus (OTS-412) that is injected directly into tumors. It is for people with solid tumors that have not responded to standard treatments, including immunotherapy. The goal is to see if the virus can shrink or control the injected tumors.
This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.
Hear when a new Advanced Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.